IDXXIDEXX LABORATORIES INC /DE

Nasdaq idexx.com


$ 480.61 $ 4.78 (1 %)    

Friday, 03-May-2024 15:59:55 EDT
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 480.6
$ 487.88
$ 0.00 x 0
$ 480.77 x 100
$ 478.54 - $ 492.33
$ 372.50 - $ 583.39
547,954
na
40.35B
$ 1.26
$ 46.56
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-22-2024 12-31-2023 10-K
3 11-01-2023 09-30-2023 10-Q
4 08-01-2023 06-30-2023 10-Q
5 05-02-2023 03-31-2023 10-Q
6 02-16-2023 12-31-2022 10-K
7 11-01-2022 09-30-2022 10-Q
8 08-02-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-16-2022 12-31-2021 10-K
11 11-02-2021 09-30-2021 10-Q
12 07-30-2021 06-30-2021 10-Q
13 05-04-2021 03-31-2021 10-Q
14 02-12-2021 12-31-2020 10-K
15 10-29-2020 09-30-2020 10-Q
16 07-31-2020 06-30-2020 10-Q
17 04-30-2020 03-31-2020 10-Q
18 02-14-2020 12-31-2019 10-K
19 10-31-2019 09-30-2019 10-Q
20 08-01-2019 06-30-2019 10-Q
21 05-01-2019 03-31-2019 10-Q
22 02-15-2019 12-31-2018 10-K
23 11-01-2018 09-30-2018 10-Q
24 08-01-2018 06-30-2018 10-Q
25 05-04-2018 03-31-2018 10-Q
26 02-16-2018 12-31-2017 10-K
27 10-31-2017 09-30-2017 10-Q
28 08-01-2017 06-30-2017 10-Q
29 04-28-2017 03-31-2017 10-Q
30 02-17-2017 12-31-2016 10-K
31 11-01-2016 09-30-2016 10-Q
32 08-02-2016 06-30-2016 10-Q
33 04-29-2016 03-31-2016 10-Q
34 02-17-2016 12-31-2015 10-K
35 10-28-2015 09-30-2015 10-Q
36 07-30-2015 06-30-2015 10-Q
37 04-28-2015 03-31-2015 10-Q
38 02-17-2015 12-31-2014 10-K
39 10-24-2014 09-30-2014 10-Q
40 07-25-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-maintains-overweight-on-idexx-laboratories-lowers-price-target-to-570

Barclays analyst Balaji Prasad maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from...

 aging-pet-population-is-solid-longer-term-tailwind-for-idexx-labs-analyst

IDEXX Laboratories reports Q1 EPS of $2.81 (up 10% Y/Y), with sales reaching $964M (7% increase). Revenue growth driven by Comp...

 idexx-laboratories-q1-2024-adj-eps-281-beats-267-estimate-sales-96400m-miss-96613m-estimate

IDEXX Laboratories (NASDAQ:IDXX) reported quarterly earnings of $2.81 per share which beat the analyst consensus estimate of $2...

 investor-activism-elanco-animal-health-settles-with-ancora-adds-new-board-members

Elanco Animal Health settles with Ancora, expanding board to 14 members, including Ancora's nominees Craig Wallace and Kath...

 jp-morgan-maintains-overweight-on-idexx-laboratories-raises-price-target-to-630

JP Morgan analyst Chris Schott maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and raises the price target from...

 barclays-maintains-overweight-on-idexx-laboratories-raises-price-target-to-655

Barclays analyst Balaji Prasad maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and raises the price target from...

 stocks-fall-as-traders-dial-back-rate-cut-bets-dollar-treasury-yields-rise-whats-driving-markets-monday

Wall Street ends week on negative note as traders revise down expectations on Fed rate cuts. Strong economic data and Fed offic...

 why-is-animal-diagnostic-focused-idexx-laboratories-stock-trading-higher-today

IDEXX Laboratories gains on Q4 2023 results. Despite challenges, Idexx demonstrates resilience in the global animal health market.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION